The National Cancer Institute, through its Clinical Proteomic Technologies for Cancer (CPTC) initiative has entered into a memorandum of understanding with the American Association for Clinical Chemistry (AACC) to join forces to promote and educate the clinical chemistry community in the area of proteomic standards and technology advances.
Partnering with AACC – an organization that represents professionals engaged in all aspects of clinical chemistry from performing laboratory tests and analyses to innovating new tests and laboratory devices – provides an effective means for CPTC to educate key clinical audiences on the need for and use of standards in multiplex-based proteomic technologies.
CPTC was established by the NCI to understand issues associated with bias and variability when conducting protein-based measurements (analytical, regulatory, and data release policies). This is being achieved through the development of new protein biomarker workflows that are reproducible, quantitative, and reliable. Through education and standardization of laboratory technologies, this partnership has the potential to reduce the amount of time and expenses needed to translate protein biomarker discoveries to clinical utility.